Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug.
Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug.
复制标题
双靶向透明质酸纳米药物的临床前评估和治疗反应监测
DOI：
10.1155/2017/4972701
复制
发表时间：
2017
影响因子：
--
通讯作者：
Gao S
中科院分区：
文献类型：
--
作者：
Chen M;Zhang W;Yuan K;Bo M;Chen B;Li L;Ma Q;Zhu L;Gao S
化疗是一种有效的癌症治疗方法，但生物相容性差，缺乏肿瘤靶向。在这里，我们通过将10-羟基喜树碱（HCPT）封装到透明质酸纳米颗粒（HANP）中来开发用于靶向癌症治疗的CD 44靶向聚合物纳米复合物。在体外，与游离HCPT相比，HANP/HCPT显示出对五种癌细胞系（包括HT 29、A549、MDA-MB-231、HepG 2和MDA-MB-435）的改善的细胞毒性。在MDA-MB-231乳腺癌异种移植物中全身给药后，相对于未给药组，HANP/HCPT给药组中的肿瘤生长被显著抑制5.25 ± 0.21倍。此外，还通过18 F-氟-2-脱氧-D-葡萄糖（[18 F] FDG）正电子发射断层扫描（PET）评估并确认了治疗反应。MDA-MB-231肿瘤在首次治疗后7天对HANP/HCPT有反应，这有利于治疗策略的调整和个性化。在用HANP/HCPT处理的小鼠中未观察到明显的全身毒性作用。总之，HANPs作为癌症化疗的靶向药物载体具有很大的前景。我们的HANP平台还可以提供其他疏水性化疗药物。
Chemotherapy is a powerful cancer treatment but suffers from poor biocompatibility and a lack of tumor targeting. Here, we developed a CD44-targeted polymeric nanocomplex by encapsulating 10-hydroxycamptothecin (HCPT) into hyaluronic acid nanoparticles (HANP) for targeted cancer therapy. In vitro, the HANP/HCPT showed improved cytotoxicity to five cancer cell lines including HT29, A549, MDA-MB-231, HepG2, and MDA-MB-435 versus free HCPT. After systemic administration into MDA-MB-231 breast cancer xenograft, tumor growth was significantly inhibited 5.25 ± 0.21 times in the HANP/HCPT treated group relative to the nontreated group. In addition, the treatment response was also accessed and confirmed by 18F-fluoro-2-deoxy-D-glucose ([18F] FDG) positron emission tomography (PET). The MDA-MB-231 tumors responded to HANP/HCPT 7 days after the first treatment, which benefits treatment strategy adjustment and personalization. No apparent systemic toxic effects were seen in mice treated with HANP/HCPT. In summary, the HANPs have great promise as a targeted drug carrier for cancer chemotherapy. Our HANP platform can also deliver other hydrophobic chemotherapy agents.
登录
查看更多内容
影响因子：
3.7
作者：
Munk Jensen M;Erichsen KD;Björkling F;Madsen J;Jensen PB;Sehested M;Højgaard L;Kjær A
通讯作者：
Kjær A
影响因子：
12.4
作者：
Zhu L;Guo N;Li Q;Ma Y;Jacboson O;Lee S;Choi HS;Mansfield JR;Niu G;Chen X
通讯作者：
Chen X
DOI：
10.1155/2011/834515
发表时间：
2011
期刊：
International journal of molecular imaging
影响因子：
--
作者：
Girgis MD;Olafsen T;Kenanova V;McCabe KE;Wu AM;Tomlinson JS
通讯作者：
Tomlinson JS
通过 18F-FLT MicroPET/CT 成像早期监测舒尼替尼在 U87MG 肿瘤异种移植物中的抗血管生成治疗反应
影响因子：
--
作者：
Bao X;Wang MW;Zhang YP;Zhang YJ
通讯作者：
Zhang YJ
影响因子：
254.7
作者：
BEATSON, GT
通讯作者：
BEATSON, GT